David A. Siegel Biotechnology

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
SEER Seer, Inc.	$142M	$1.08 Million 0.0% of portfolio	549,100	Q3 2024 Added 27.08%
BBIO Bridge Bio Pharma, Inc.	$3.47B	$1.04 Million 0.0% of portfolio	40,855	Q3 2024 Reduced 83.84%
HUMA Humacyte, Inc.	$463M	$1.02 Million 0.0% of portfolio	188,400	Q3 2024 Reduced 28.72%
ACET Adicet Bio, Inc.	$36M	$1.02 Million 0.0% of portfolio	706,639	Q3 2024 Added 16.77%
VTYX Ventyx Biosciences, Inc.	$105M	$1.01 Million 0.0% of portfolio	465,400	Q3 2024 Added 118.5%
AMLX Amylyx Pharmaceuticals, Inc.	$310M	$1 Million 0.0% of portfolio	309,500	Q3 2024 Reduced 73.18%
REGN Regeneron Pharmaceuticals, Inc.	$79.1B	$946,000 0.0% of portfolio	900	Q3 2024 Reduced 10.0%
MRSN Mersana Therapeutics, Inc.	$198M	$920,000 0.0% of portfolio	486,800	Q3 2024 Reduced 32.32%
ALXO Alx Oncology Holdings Inc	$57.5M	$910,000 0.0% of portfolio	500,500	Q3 2024 Added 640.38%
VERV Verve Therapeutics, Inc.	$291M	$893,000 0.0% of portfolio	184,600	Q3 2024 Reduced 22.66%
STTK Shattuck Labs, Inc.	$42.4M	$886,000 0.0% of portfolio	253,900	Q3 2024 Added 601.38%
ABSI Absci Corp	$238M	$885,000 0.0% of portfolio	231,700	Q3 2024 Reduced 2.97%
CRDF Cardiff Oncology, Inc.	$109M	$884,000 0.0% of portfolio	331,200	Q3 2024 Added 60.0%
KOD Kodiak Sciences Inc.	$322M	$869,000 0.0% of portfolio	333,300	Q3 2024 Added 10.95%
SAGE Sage Therapeutics, Inc.	$307M	$868,000 0.0% of portfolio	120,399	Q3 2024 Reduced 20.05%
CELC Celcuity Inc.	$197M	$820,000 0.0% of portfolio	55,000	Q3 2024 Added 179.19%
GOSS Gossamer Bio, Inc.	$65.8M	$792,000 0.0% of portfolio	800,000	Q3 2024 Reduced 2.9%
RLMD Relmada Therapeutics, Inc.	$80.1M	$785,000 0.0% of portfolio	242,500	Q3 2024 Reduced 17.09%
SWTX Spring Works Therapeutics, Inc.	$2.43B	$784,000 0.0% of portfolio	24,500	Q3 2024 Reduced 41.67%
RGNX Regenxbio Inc.	$415M	$713,000 0.0% of portfolio	68,000	Q3 2024 Reduced 10.41%
IMTX Immatics N.V.	$579M	$682,000 0.0% of portfolio	59,800	Q3 2024 Reduced 40.38%
RYTM Rhythm Pharmaceuticals, Inc.	$3.31B	$670,000 0.0% of portfolio	12,800	Q3 2024 Added 43.82%
RCUS Arcus Biosciences, Inc.	$1.06B	$662,000 0.0% of portfolio	43,300	Q3 2024 Added 13.65%
VNDA Vanda Pharmaceuticals Inc.	$288M	$659,000 0.0% of portfolio	140,600	Q3 2024 Reduced 34.33%
FOLD Amicus Therapeutics, Inc.	$2.71B	$640,000 0.0% of portfolio	59,976	Q3 2024 Reduced 28.32%
LRMR Larimar Therapeutics, Inc.	$256M	$636,000 0.0% of portfolio	97,124	Q3 2024 Reduced 26.49%
ORMP Oramed Pharmaceuticals Inc.	$90.9M	$623,000 0.0% of portfolio	255,600	Q3 2024 Reduced 1.35%
IMAB I Mab	$78.1M	$619,000 0.0% of portfolio	499,300	Q3 2024 Reduced 13.41%
ORIC Oric Pharmaceuticals, Inc.	$380M	$596,000 0.0% of portfolio	58,200	Q3 2024 Reduced 27.34%
PTGX Protagonist Therapeutics, Inc	$2.28B	$543,000 0.0% of portfolio	12,100	Q3 2024 Reduced 89.62%
HOWL Werewolf Therapeutics, Inc.	$56.1M	$543,000 0.0% of portfolio	256,300	Q3 2024 Added 7.1%
ALT Altimmune, Inc.	$426M	$542,000 0.0% of portfolio	88,400	Q3 2024 Added 27.38%
GBIO Generation Bio Co.	$80.8M	$536,000 0.0% of portfolio	217,100	Q3 2024 Reduced 20.18%
VCYT Veracyte, Inc.	$2.83B	$520,000 0.0% of portfolio	15,300	Q3 2024 Reduced 25.0%
KALV Kal Vista Pharmaceuticals, Inc.	$250M	$443,000 0.0% of portfolio	38,322	Q3 2024 Reduced 39.29%
ALVR Allovir, Inc.	$51.2M	$411,000 0.0% of portfolio	508,300	Q3 2024 Reduced 19.83%
PBYI Puma Biotechnology, Inc.	$137M	$410,000 0.0% of portfolio	161,000	Q3 2024 Added 18.91%
KROS Keros Therapeutics, Inc.	$1.44B	$400,000 0.0% of portfolio	6,900	Q3 2024 Reduced 61.24%
AKRO Akero Therapeutics, Inc.	$1.52B	$398,000 0.0% of portfolio	13,900	Q3 2024 Reduced 23.2%
ITOS I Teos Therapeutics, Inc.	$296M	$386,000 0.0% of portfolio	37,900	Q3 2024 Added 108.24%
RPHM Reneo Pharmaceuticals, Inc.	$41.1M	$384,000 0.0% of portfolio	226,300	Q3 2024 Added 202.14%
ACLX Arcellx, Inc.	$3.86B	$375,000 0.0% of portfolio	4,500	Q3 2024 Reduced 15.09%
BLUE Bluebird Bio, Inc.	$27M	$370,000 0.0% of portfolio	713,100	Q3 2024 Reduced 15.73%
IKNA Ikena Oncology, Inc.	$62M	$349,000 0.0% of portfolio	202,100	Q3 2024 Added 16.69%
ZLAB Zai Lab LTD	$2.59B	$337,000 0.0% of portfolio	14,000	Q3 2024 New
CRVS Corvus Pharmaceuticals, Inc.	$379M	$323,000 0.0% of portfolio	61,300	Q3 2024 Reduced 45.94%
VIR Vir Biotechnology, Inc.	$944M	$320,000 0.0% of portfolio	42,800	Q3 2024 Reduced 41.77%
URGN Uro Gen Pharma Ltd.	$271M	$311,000 0.0% of portfolio	24,500	Q3 2024 Reduced 1.61%
AXSM Axsome Therapeutics, Inc.	$4.23B	$305,000 0.0% of portfolio	3,400	Q3 2024 New
CGEM Cullinan Oncology, Inc.	$572M	$299,000 0.0% of portfolio	17,900	Q3 2024 Reduced 13.94%

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account